Q32 Bio Inc. (QTTB): Capital Expenditures
$0
Year ended 2025-12-31
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | -100.0% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $75.0K | n/m | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $5.0K | -99.6% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $1.28M | -46.4% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $2.40M | -35.8% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $3.73M | -82.9% | 2022-03-23, From 2020-01-01 |
| 2019-12-31 | $21.83M | -12.5% | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | $24.94M | n/m | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $1.96M | n/a | 2019-03-12, From 2017-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $0 | -100.0% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $4.32M | +156.1% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $171.0K | -88.4% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $12.01M | +832.5% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $29.0K | -87.3% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $0 | -100.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $79.0K | n/a |
| Journey Medical Corp (DERM) | 2024-12-31 | $15.00M | +200.0% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $1.05M | +39.0% |
Compare QTTB, AGIO, NKTR, OCUL side by side · Screen every company in Pharmaceutical Preparations ↗